POM Investment Strategies’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

POM Investment Strategies’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3	Closed	-$75	–	345
2024 Q3	$75	Buy	+3	New	+$91	﹤0.01%	307

Other funds holding BIS

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

POM Investment Strategies's BIS Position: Q4 2024 in Review

POM Investment Strategies sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2024, closing a stake of 3 shares — an estimated $75 sold.

POM Investment Strategies first reported a position in BIS in Q3 2024 and held it in 1 quarter. The position peaked at $75 in Q3 2024. 6 funds tracked by Wall St. Rank hold BIS as of Q4 2024.

POM Investment Strategies reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2024 after selling out during the quarter.
POM Investment Strategies sold 3 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2024, an estimated $75.
POM Investment Strategies first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2024 and held it in 1 quarter.
POM Investment Strategies's ProShares UltraShort NASDAQ Biotechnology position peaked at $75 in Q3 2024.
6 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2024.

Based on POM Investment Strategies's 13F filing for Q4 2024, filed 29 Jan 2025.